Medicinal composition capsules of valsartan and hydrochlorothiazide and preparation method for capsules

A technology of hydrochlorothiazide and a composition, applied in the field of pharmaceutical preparations, can solve the problems of not disclosing the activity of soybean phosphatidylcholineylserine, affecting the combined use of valgetan and hydrochlorothiazide, and achieving liver protection, good therapeutic effect, and absorption capacity. strong effect

Active Publication Date: 2012-09-19
CHONGQING CONQUER PHARML
View PDF5 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although soybean phosphatidylcholinelserine and phosphatidylcholine are mentioned in the patent whose publication number is CN101972263A, soybean phosphatidylcholinelserine is not disclosed to have activity in the application documents, and soybean phosphatidylcholinelserine and phosphatidylcholine Alkali is only an auxiliary material in the preparation
According to reports, the peak blood concentration of hydrochlorothiazide in the human body is significantly faster than that of valsartan, which affects the combined use of valgitan and hydrochlorothiazide

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition capsules of valsartan and hydrochlorothiazide and preparation method for capsules
  • Medicinal composition capsules of valsartan and hydrochlorothiazide and preparation method for capsules
  • Medicinal composition capsules of valsartan and hydrochlorothiazide and preparation method for capsules

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 2

[0017] Embodiment 2 Preparation of valsartan and hydrochlorothiazide pharmaceutical composition capsule

[0018] Weigh 8 g of hydrochlorothiazide, 60 g of phosphatidylcholine, 30 g of microcrystalline fiber, 8 g of polyacrylic acid resin NE30D, and 6 g of magnesium stearate. Mix hydrochlorothiazide, phosphatidylcholine, magnesium stearate and microcrystalline fiber evenly, and use 50% polyacrylic acid resin NE30D as a wetting agent / adhesive to prepare a soft material; put the soft material into the extruder Medium extrusion, the extrudate is placed in a spheronizer to make a pellet core, and dried to obtain a skeleton slow-release pellet core; the skeleton slow-release pellet core is placed in a fluidized bed, and the bottom spray method is used to spray polyacrylic acid resin NE30D coating to obtain slow-dissolving pellets.

[0019] Take by weighing valsartan 20g, PVPP 20g, microcrystalline cellulose 40g, sodium lauryl sulfate 3g, povidone K30 6g, magnesium stearate 3g, mi...

Embodiment 3

[0024] Example 3 Decompression and investigation of kidney protection

[0025] 40 12-week-old spontaneously hypertensive rats (SHR), 10 Wistar.Kyoto (WKY) rats of the same age, all male, were randomly divided into 3 groups, SHR control group (10 rats) SHR administration treatment group ( 10 rats) and the SHR valsartan control group (10 rats) and the SHR valsartan and hydrochlorothiazide control group (10 rats), first adaptively fed for 3 days, and then the valsartan control group received valsartan 30 mg / (kg· d) intragastric administration, SHR valsartan and hydrochlorothiazide were given a mixture of 22 mg valsartan and hydrochlorothiazide 8 mg / (kg d) intragastric administration, and the SHR drug treatment group adopted the drug group I described in Example 1 according to the valsartan Content of 15mg / (kg d), SHR control group and WKY group were given the same amount of distilled water orally every day, and the two kinds of rats were purchased from the Experimental Animal B...

Embodiment 4

[0047] Example 4 Comparison of Effects of Lowering Blood Pressure and Reversing Left Ventricular Hypertrophy

[0048] The 30 SHRs were randomly divided into 5 groups, 6 in each group, 1 group was the control group, and the remaining 4 groups were the medication groups. The medication groups were given valsartan 8mg / (kg·d) as the SHR valsartan control group, valsartan 8mg and hydrochlorothiazide 2mg mixture mg / (kg·d) as the SHR valsartan and hydrochlorothiazide control group and The drug group I described in Example 1 was used as the SHR drug treatment group according to the valsartan content of 8 mg / (kg·d). Rats were fed with normal pellet chow. Every day at 9 o'clock in the morning, the medicine was added with a certain amount of normal saline, and then intragastrically administered. Both the control group and the WKY group were intragastrically administered with the same amount of normal saline for 4 weeks.

[0049] The tail artery systolic pressure and body weight (BW)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses medicinal composition capsules of valsartan and hydrochlorothiazide. The capsules are prepared by mixing instant granules made of the valsartan and slowly dissolved pellets made of the hydrochlorothiazide and filling. The medicinal composition capsules are strong in absorption capability of active ingredients, have a good treatment effect on primary hypertension, and have effects of protecting liver and treating left ventricular hypertrophy caused by hypertension.

Description

technical field [0001] The present invention relates to a kind of medicine preparation, relate to a kind of valsartan and hydrochlorothiazide pharmaceutical composition capsule and preparation method thereof more specifically. technical background [0002] According to the ESH / ESC guidelines on the prevention and treatment of hypertension, the target blood pressure of uncomplicated hypertensive patients should be controlled at <140 / 90mmHg; patients with diabetes, kidney disease or other high-risk factors (such as cerebrovascular accident or myocardial infarction) The target blood pressure needs to be controlled at <130 / 80mmHg. In order to achieve the above treatment target value, most of the current hypertension guidelines recommend the combined use of two antihypertensive drugs in the initial treatment. However, many studies have shown that only about 1 / 3 of hypertensive patients can achieve the goal under the dual antihypertensive drug regimen. [0003] Chinese Pat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/685A61K31/549A61K31/41A61K9/48A61K9/16A61P9/12
Inventor 梅勇罗磊何远东马贵勇姜艳红杨莉陈丽李小林
Owner CHONGQING CONQUER PHARML
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap